Howard K. Surks

Cardiology
750 Washington St # 8080
Boston, MA 02111

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.

Journal: JACC. Heart failure
Published: March 10, 2025

First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.

First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.

Journal: Clinical and translational science
Published: October 03, 2022

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.

Journal: Clinical and experimental immunology
Published: July 27, 2018

Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials.

Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials.

Journal: JACC. Heart failure
Published: April 06, 2018

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.

Journal: Journal of diabetes science and technology
Published: January 24, 2018

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Journal: Gene regulation and systems biology
Published: November 21, 2016

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Journal: Circulation
Published: September 01, 2016

Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.

Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.

Journal: Journal of the American Heart Association
Published: June 12, 2016

Pericyte contractility controls endothelial cell cycle progression and sprouting: insights into angiogenic switch mechanics.

Pericyte contractility controls endothelial cell cycle progression and sprouting: insights into angiogenic switch mechanics.

Journal: American journal of physiology. Cell physiology
Published: August 22, 2014

Steroid-sensitive gene 1 is a novel cyclic GMP-dependent protein kinase I substrate in vascular smooth muscle cells.

Steroid-sensitive gene 1 is a novel cyclic GMP-dependent protein kinase I substrate in vascular smooth muscle cells.

Journal: The Journal of biological chemistry
Published: July 09, 2013

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.

Journal: Atherosclerosis
Published: January 31, 2013

Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.

Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.

Journal: Clinical pharmacology and therapeutics
Published: December 02, 2011
Showing 1-12 of 12

Last Updated: 09/26/2026